Company: IMRX
Filing Date: 2025-09-25
Form Type: 424B5
Source: 0001104659-25-093438
Chunk: 8

Company: Immuneering Corp
Filing Date: 2025-09-25
Form: 424B5
Chunk 8
---
 well tolerated. As of the Cutoff Date, Grade ≥ 3 treatment-emergent adverse events, or TEAEs, observed in 10% or greater of patients in the 320 mg ITT Population consisted of Anemia (eight patients or 24%) and Neutropenia (six patients or 18%). Grade ≥ 3 TEAEs observed in less than 10% of patients in the 320 mg ITT Population consisted of Fatigue (6%), Vomiting (3%), Febrile Neutropenia (3%), Hypokalemia (3%) and Nausea (3%). No Grade 5 TEAEs were observed in this patient population and no new safety signals were identified.

We expect the following near-term anticipated milestones related to atebimetinib:

•

Regulatory feedback on our pivotal Phase 3 clinical trial plans in the fourth quarter of 2025.

•

An announcement of further updated OS and PFS data from first-line pancreatic cancer patients (N=34) treated with atebimetinib in combination with mGnP, including at a scientific conference in 2026.

•

Subject to the regulatory feedback described above, the initiation of a pivotal Phase 3 trial of atebimetinib in combination with mGnP in first-line pancreatic cancer by the end of 2025, and the dosing the first patient therein by mid-2026.

•

Subject to additional regulatory feedback, the initiation of additional atebimetinib clinical trial combination arms in 2026, including in non-small cell lung cancer.

Concurrent Private Placement

On September 24, 2025, we entered into a securities purchase agreement with Aventis Inc. (referred to herein as the Investor), a wholly owned subsidiary of Sanofi, a French société anonyme, pursuant to which the Investor agreed to purchase, subject to certain conditions, up to $25.0 million of our Class A common stock, or in certain situations in lieu of shares of Class A common stock, shares of our non-voting Class B common stock, in a private placement. Under the terms of the securities purchase agreement, the private placement is subject to and contingent upon the closing of a firm commitment underwritten public offering by us of our Class A common stock that results in gross proceeds to us of at least $75.0 million and the pricing of which is publicly announced in a press release issued by us on or before September 26, 2025 (referred to herein as